RAB3A: A Potential Drug Target and Biomarker for Cancer (G5864)

Target Name: RAB3A

NCBI ID: G5864

RAB3A

Other Name(s): RAB3A, member RAS oncogene family | Ras-related protein Rab-3A | RAB3A_HUMAN | RAS-associated protein RAB3A

RAB3A: A Potential Drug Target and Biomarker for Cancer

Rab3A is a gene that encodes a protein known as Rab3A, which is a member of the RAS (Ras-associated protein of 22kDa) oncogene family. The RAS oncogene family is a group of proteins that are known to promote cancer cell growth and survival. Rab3A is a non-coding RNA molecule that has been shown to play a role in regulating cell proliferation and survival.

Recent studies have identified Rab3A as a potential drug target for cancer. By inhibiting the activity of Rab3A, researchers have found that they can reduce the growth and survival of cancer cells. This suggests that Rab3A could be a useful target for cancer treatment.

In addition to its potential as a drug target, Rab3A has also been identified as a biomarker for cancer. By analyzing the expression of Rab3A in cancer cells, researchers have found that the expression level of Rab3A is often higher in cancer cells than in normal cells. This suggests that Rab3A could be a useful biomarker for cancer diagnosis and monitoring.

The RAS oncogene family is a group of proteins that are known to promote cancer cell growth and survival. The RAS gene is located on chromosome 11 and encodes a protein that is involved in cell signaling. The RAS gene has four splice variants, which are designated as RAS1, RAS2, RAS3, and RAS4.

RAS1 and RAS2 are the most abundant splice variants of the RAS gene. RAS1 is a 21-kDa protein that is involved in cell signaling, while RAS2 is a 22-kDa protein that is involved in cell signaling and adhesion. RAS3 and RAS4 are less abundant splice variants of the RAS gene.

The RAS oncogene family has been implicated in many aspects of cancer biology. For example, RAS has been shown to promote the growth and survival of many types of cancer cells. In addition, RAS has been shown to play a role in the development of cancer stem cells.

In conclusion, Rab3A is a non-coding RNA molecule that has been shown to play a role in regulating cell proliferation and survival. In addition to its potential as a drug target, Rab3A has also been identified as a biomarker for cancer. Further research is needed to fully understand the role of Rab3A in cancer biology and to develop effective treatments.

Protein Name: RAB3A, Member RAS Oncogene Family

Functions: Small GTP-binding protein that plays a central role in regulated exocytosis and secretion. Controls the recruitment, tethering and docking of secretory vesicles to the plasma membrane (By similarity). Upon stimulation, switches to its active GTP-bound form, cycles to vesicles and recruits effectors such as RIMS1, RIMS2, Rabphilin-3A/RPH3A, RPH3AL or SYTL4 to help the docking of vesicules onto the plasma membrane (By similarity). Upon GTP hydrolysis by GTPase-activating protein, dissociates from the vesicle membrane allowing the exocytosis to proceed (By similarity). Stimulates insulin secretion through interaction with RIMS2 or RPH3AL effectors in pancreatic beta cells (By similarity). Regulates calcium-dependent lysosome exocytosis and plasma membrane repair (PMR) via the interaction with 2 effectors, SYTL4 and myosin-9/MYH9 (PubMed:27325790). Acts as a positive regulator of acrosome content secretion in sperm cells by interacting with RIMS1 (PubMed:22248876, PubMed:30599141). Also plays a role in the regulation of dopamine release by interacting with synaptotagmin I/SYT (By similarity). Interacts with MADD (via uDENN domain); the GTP-bound form is preferred for interaction (By similarity)

The "RAB3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets